Hypertrophic cardiomyopathy is a heart condition where the heart muscle becomes abnormally thick. This makes it harder for the heart to work correctly. Obstructive hypertrophic cardiomyopathy (oHCM) ...

Factors affecting Camzyos cost include your treatment plan, insurance coverage, pharmacy, and whether Camzyos has a savings program that you qualify for. The Camzyos Co-Pay Program is available for ...

Camzyos (mavacamten) is a brand-name capsule that’s prescribed for obstructive hypertrophic cardiomyopathy in adults. It has a boxed warning about the risk of heart failure. To help manage this, the ...

Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...

Camzyos (mavacamten) is a prescription drug that works to treat obstructive hypertrophic cardiomyopathy (HCM) by relaxing your heart muscle, allowing it to pump blood more easily. Doctors prescribe ...

"In addition to the established efficacy of CAMZYOS, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clinical and real-world data and more than 15 ...

Findings from COLLIGO-HCM reinforce Camzyos’ efficacy and safety profile in reducing left ventricular outflow tract (LVOT) obstruction and improving symptom burden in a racially diverse, global ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. The Food and Drug Administration (FDA) has approved Camzyos ™ (mavacamten) for the treatment of adults with ...

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...